Price (delayed)
$1.45
Market cap
$36.12M
P/E Ratio
N/A
Dividend/share
$0.02
EPS
-$2.11
Enterprise value
-$9.81M
Rafael Holdings is focused on development of novel cancer therapies. The Company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through
Special dividends are included in TTM DPS and yield
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.